Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Health

New Report Available: Sprycel (Prostate Cancer) - Forecast and Market Analysis to 2022


Print article Print article
2013-02-28 12:38:18 - Fast Market Research recommends "Sprycel (Prostate Cancer) - Forecast and Market Analysis to 2022" from GlobalData, now available

GlobalData has released its new PharmaPoint Drug Evaluation report, "Sprycel (Prostate Cancer) - Forecast and Market Analysis to 2022". The recent approvals of second-line metastatic castration-resistant prostate cancer (mCRPC) therapies like J&J's Zytiga (abiraterone acetate) and Medivation/Astellas' Xtandi (enzalutamide) will drive strong market growth over the next decade. These safe and orally administered treatments will provide safety and convenience benefits over the current standard of care, chemotherapy with docetaxel, while prolonging the overall survival of patients with mCRPC. The December 12, 2012 FDA approval of Zytiga for the added indication of chemotherapy-naive mCRPC marks the onset of a new treatment paradigm for the disease, in which chemotherapy is relegated to second-line therapy and beyond. For patients with earlier-stage prostate cancer,

androgen deprivation therapy with LHRH agonists and first-generation antiandrogens remains the standard of care for suppressing testosterone levels and temporarily controlling the disease.


Full Report Details at
- www.fastmr.com/prod/544199_sprycel_prostate_cancer_forecast_and_ ..


BMS' Sprycel is in development for use in combination with docetaxel and prednisone as a first-line treatment for mCRPC. It is currently approved for the treatment of Chronic Myeloid Leukemia (CML) and Acute Lymphoblastic Leukemia (ALL). Sprycel is small-molecule kinase inhibitor administered orally once daily that inhibits the activity of BCR-ABL and the SRC family of kinases, as well as c-KIT, EPHA2, and PDGFRB.

Scope

* Overview of Prostate cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
* Detailed information on Sprycel including product description, safety and efficacy profiles as well as a SWOT analysis.
* Sales forecast for Sprycel for the top nine countries from 2012 to 2022.
* Sales information covered for the US, Japan, UK, France, Germany, Spain, Italy , Canada, and Australia

Reasons to buy

* Understand and capitalize by identifying products that are most likely to ensure a robust return
* Stay ahead of the competition by understanding the changing competitive landscape for Prostate cancer
* Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
* Make more informed business decisions from insightful and in-depth analysis of Sprycel performance
* Obtain sales forecast for Sprycel from 2012-2022 in nine markets (US, Japan, UK, France, Germany, Spain, Italy , Canada, and Australia)

Report Table of Contents:

1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.1.3 Prognosis
3.1.4 Quality of Life
3.2 Symptoms
4 Disease Management
4.1 Diagnosis and Referral Overview
4.2 Treatment Overview
4.2.1 Conservative Management Strategies
4.2.2 Localized Treatments
4.2.3 Hormone Therapy
4.2.4 Drug Therapies
5 Competitive Assessment
5.1 Overview
5.2 Strategic Competitor Assessment
6 Opportunity and Unmet Need
6.1 Overview
6.2 Efficacy at Prolonging Overall Survival
6.3 Safety
6.4 Mitigation of Symptoms
6.5 Cost
6.6 Convenient Routes of Administration
6.7 Accurate Diagnostic Tests and Surveillance Tools
6.8 Unmet Needs Gap Analysis
6.9 Opportunity: Targeting Early-Stage, Hormone-Sensitive Prostate Cancer
7 Pipeline Assessment
7.1 Overview
7.2 Promising Drugs in Clinical Development
8 Sprycel (dasatinib)
8.1 Overview
8.2 Efficacy
8.3 Safety
8.4 Dosing and Formulation
8.5 Potential Clinical Positioning
8.6 Potential Commercial Positioning
8.7 Pricing and Reimbursement
8.8 SWOT Analysis
8.9 Forecast
9 Appendix
9.1 Bibliography
9.2 Abbreviations
9.3 Methodology
9.4 Forecasting Methodology
9.4.1 Number of Prostate Cancer Patients Currently Seeking Treatment
9.4.2 Percent Drug-treated Patients
9.4.3 Percent Hormone Therapy-Treated Patients
9.4.4 General Pricing Assumptions
9.4.5 Individual Drug Assumptions
9.4.6 Generic Erosion
9.4.7 Pricing of Pipeline Agents
9.5 Physicians and Specialists Included in This Study
9.6 Survey of Prescribing Physicians
9.7 About the Authors
9.7.1 Authors
9.7.2 Global Head of Healthcare
9.8 About GlobalData
9.9 Contact Us
9.10 Disclaimer

List of Tables

1.1 List of Tables
Table 1: Stage Distribution of Prostate Cancer at Diagnosis in Selected Major Markets
Table 2: Global Variations in Recommendations on Routine PSA Screening
Table 3: Most Commonly Followed Treatment Guidelines for Prostate Cancer, 2012
Table 4: Most Commonly Prescribed Drugs for Prostate Cancer by Class in the Global Markets, 2012
Table 5: Leading Treatments for Prostate Cancer, 2012
Table 6: Overall Unmet Needs, Hormone-Sensitive Prostate Cancer - Current Level of Attainment
Table 7: Overall Unmet Needs, CRPC - Current Level of Attainment
Table 8: Clinical Unmet Needs - Gap Analysis, 2012
Table 9: Prostate Cancer - Phase III Pipeline, 2012
Table 10: Comparison of Therapeutic Classes in Development for Prostate Cancer, 2012
Table 11: Product Profile - Sprycel
Table 12: Sprycel SWOT Analysis, 2012
Table 13: Global Sales Forecasts ($m) for Sprycel, 2012-2022
Table 14: Physicians Surveyed, By Country

List of Figures

1.2 List of Figures
Figure 1: General Treatment Algorithm for Prostate Cancer, 2012
Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in Prostate Cancer, 2012-2022

About GlobalData

GlobalData is a leading provider of global business intelligence including market, competitor, product and customer information. It provides in-depth research, analysis, data and forecasts through a range of interactive online databases, reports and management briefings. GlobalData has a large team of experienced research and analysis, consulting, and marketing experts. It has a global presence, including key offices in the US, Europe and Asia. The group has over 50 years of experience of delivering market intelligence data and analysis and a highly experienced senior management team. View more research from GlobalData at www.fastmr.com/catalog/publishers.aspx?pubid=1015

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.


Author:
Bill Thompson
e-mail
Web: www.fastmr.com
Phone: 18008448156

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com | BidVertiser